AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22746337 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine 5 mg
Number of subjects: 38
Study 22746337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 22746337 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 38
Study 21480974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose management
Number of subjects: 300
Study 21480974 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucose management
Number of subjects: 300
Study 19726643 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 22
Study 19726643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 19726643 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 22
Study 17566172 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatic oils for massage
Number of subjects: 31
Study 15195048 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral spray lubricant applied before bedtime
Number of subjects: 40
Study 15195048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal strip designed to maintain nasal valve patency
Number of subjects: 40
Study 15195048 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-positioning pillow
Number of subjects: 40
Study 15195048 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 40
Study 11727508 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel erythropoiesis stimulating protein (NESP)
Number of subjects: 0
Study 11727508 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (rhuEPO)
Number of subjects: 0
Study 9012705 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal of acenocoumarol (AW)
Number of subjects: 20
Study 9012705 — intervention group
Group type: COMPARATOR
Intervention: Gradual withdrawal of acenocoumarol (GW)
Number of subjects: 20
Study 8254783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 100 mg at night for 6 months
Number of subjects: 21
Study 8254783 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 21
Study 3303785 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 54
Study 3303785 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection therapy (CIT)
Number of subjects: 54
Study 2178389 — intervention group
Group type: EXPERIMENTAL
Intervention: Acorns (25 g carbohydrate portion)
Number of subjects: 8
Study 2178389 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn (25 g carbohydrate portion)
Number of subjects: 8
Study 1026423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish protein concentrate (FPC)
Number of subjects: 72
Study 1026423 — intervention group
Group type: COMPARATOR
Intervention: Cow-milk protein concentrate (Casilan)
Number of subjects: 72
Study 31650286 — intervention group
Group type: EXPERIMENTAL
Intervention: Real intermittent theta burst stimulation (iTBS)
Number of subjects: 10
Study 31650286 — intervention group
Group type: COMPARATOR
Intervention: Sham intermittent theta burst stimulation (iTBS)
Number of subjects: 10
Study 27704683 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous titanium granule (PTG) with rotary titanium brush and platelet rich fibrin (PRF) membrane
Number of subjects: 22
Study 27704683 — intervention group
Group type: COMPARATOR
Intervention: Xenograft bone substitute with collagen membrane and PRF membrane
Number of subjects: 22
Study 27704683 — intervention group
Group type: EXPERIMENTAL
Intervention: PTG
Number of subjects: 22
Study 26024575 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene in capsule
Number of subjects: 20
Study 26024575 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato paste
Number of subjects: 20
Study 26024575 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 23121338 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid therapy: pantoprazole 40 mg/b.i.d. and amoxicillin 1 g/b.i.d. for 14 days plus 500 mg clarithromycin and 500 mg tinidazole, both twice daily for the last 7 days
Number of subjects: 420
Study 23121338 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy: 40 mg pantoprazole/b.i.d. for 10 days and 1 g amoxicillin/b.i.d. for the first 5 days, followed by 500 mg clarithromycin/b.i.d. and 500 mg tinidazole/b.i.d. for the last 5 days
Number of subjects: 420
Study 21817932 — intervention group
Group type: COMPARATOR
Intervention: CIS map for 4 weeks
Number of subjects: 31
Study 21817932 — intervention group
Group type: EXPERIMENTAL
Intervention: FSP map for 4 weeks
Number of subjects: 31
Study 19094067 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (4.8 pmol/kg per min)
Number of subjects: 8
Study 19094067 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8
Study 19094067 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 8
Study 17409891 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation plus chemotherapy
Number of subjects: 157
Study 17409891 — intervention group
Group type: COMPARATOR
Intervention: Radiation
Number of subjects: 157
Study 14872448 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 11160760 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of memantine
Number of subjects: 40
Study 11160760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9283163 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 2 mg
Number of subjects: 421
Study 9283163 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 4 mg
Number of subjects: 421
Study 9283163 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg
Number of subjects: 421
Study 9283163 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 6 mg
Number of subjects: 421
Study 9283163 — intervention group
Group type: COMPARATOR
Intervention: Control (no epidural morphine)
Number of subjects: 421
Study 7509261 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of urtica/pygeum preparation (300 mg of Urtica dioica root extract combined with 25 mg of Pygeum africanum bark extract)
Number of subjects: 134
Study 7509261 — intervention group
Group type: COMPARATOR
Intervention: Half the standard dose of urtica/pygeum preparation
Number of subjects: 134
Study 3080461 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocal supplemented with NaCl to give 2 g Na/day (Diet B)
Number of subjects: 15
Study 3080461 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupplemented Isocal providing 1 g Na/day (Diet C)
Number of subjects: 15
Study 3080461 — intervention group
Group type: COMPARATOR
Intervention: Mixed foods (3-6 g Na/day) orally before gastrostomy (Diet A)
Number of subjects: 15
Study 3080461 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from Diet C to Diet B
Number of subjects: 15
Study 29088015 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 11
Study 29088015 — intervention group
Group type: COMPARATOR
Intervention: Endurance exercise
Number of subjects: 11
Study 28528561 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 321
Study 28528561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 26418303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialyser-based autotransfusion system
Number of subjects: 104
Study 26418303 — intervention group
Group type: COMPARATOR
Intervention: Cell saver system
Number of subjects: 104
Study 22462496 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Oss collagen (augmented) after 4 weeks
Number of subjects: 33
Study 22462496 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Oss collagen (augmented) after 12 weeks
Number of subjects: 33
Study 22462496 — intervention group
Group type: COMPARATOR
Intervention: Non-augmented (ungrafted) after 4 weeks
Number of subjects: 33
Study 22462496 — intervention group
Group type: COMPARATOR
Intervention: Non-augmented (ungrafted) after 12 weeks
Number of subjects: 33
Study 21962092 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide HFA (2 puffs twice daily, 85 μg/puff)
Number of subjects: 218
Study 21962092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 21962092 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide HFA
Number of subjects: 218
Study 18544984 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg
Number of subjects: 0
Study 18544984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18544984 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Number of subjects: 0
Study 16327016 — intervention group
Group type: EXPERIMENTAL
Intervention: ET(A)-receptor antagonist (BQ-123)
Number of subjects: 12
Study 16327016 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (enalapril)
Number of subjects: 12
Study 16327016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12218779 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly expressed juice of Echinacea purpurea herbs
Number of subjects: 40
Study 12218779 — intervention group
Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 40
Study 9857663 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase plasminogen activator (u-PA) concentration and activity in plasma
Number of subjects: 40
Study 9857663 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase plasminogen activator (u-PA) concentration and activity in patients with IIIb stage of cancer
Number of subjects: 40
Study 9857663 — intervention group
Group type: COMPARATOR
Intervention: Healthy adults (control group)
Number of subjects: 40
Study 7824708 — intervention group
Group type: EXPERIMENTAL
Intervention: Transluminal angioplasty coupled with thrombectomy
Number of subjects: 48
Study 7824708 — intervention group
Group type: COMPARATOR
Intervention: Surgical revision coupled with thrombectomy
Number of subjects: 48
Study 2218148 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training during a postgraduate course in obstetrics and gynaecology
Number of subjects: 0
Study 2218148 — intervention group
Group type: COMPARATOR
Intervention: Control group (senior obstetrician)
Number of subjects: 0
Study 692299 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 sec rest period
Number of subjects: 22
Study 692299 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 sec rest period
Number of subjects: 22
Study 692299 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 sec rest period
Number of subjects: 22
Study 692299 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 sec rest period
Number of subjects: 22
Study 692299 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 sec rest period
Number of subjects: 22
Study 692299 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 sec rest period
Number of subjects: 22
Study 692299 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 sec rest period
Number of subjects: 22
Study 692299 — intervention group
Group type: EXPERIMENTAL
Intervention: 640 sec rest period
Number of subjects: 22
Study 692299 — intervention group
Group type: EXPERIMENTAL
Intervention: 1280 sec rest period
Number of subjects: 22
Study 692299 — intervention group
Group type: EXPERIMENTAL
Intervention: 2560 sec rest period
Number of subjects: 22
Study 31085788 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B liposomal gel
Number of subjects: 0
Study 31085788 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin sulfate liposomal gel
Number of subjects: 0
Study 31085788 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Number of subjects: 0
Study 31085788 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight option of photodynamic therapy
Number of subjects: 0
Study 30396624 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Practice (experimental group)
Number of subjects: 0
Study 30396624 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training (control group)
Number of subjects: 0
Study 27128820 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% ethanol locks
Number of subjects: 305
Study 27128820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) evaluation
Number of subjects: 305
Study 24561769 — intervention group
Group type: EXPERIMENTAL
Intervention: Suplatast tosilate
Number of subjects: 27
Study 24561769 — intervention group
Group type: COMPARATOR
Intervention: Mequitazine
Number of subjects: 27
Study 22241289 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with fast track care (LFT)
Number of subjects: 79
Study 22241289 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with standard care (LS)
Number of subjects: 79
Study 22241289 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery with fast track care (OFT)
Number of subjects: 79
Study 22241289 — intervention group
Group type: COMPARATOR
Intervention: Open surgery with standard care (OS)
Number of subjects: 79
Study 22241289 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 79
Study 21143869 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided treatment
Number of subjects: 800
Study 21143869 — intervention group
Group type: COMPARATOR
Intervention: Standard group (physician's assessment)
Number of subjects: 800
Study 17106066 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV+RTV (n=12)
Number of subjects: 32
Study 17106066 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV+no PI (n=10)
Number of subjects: 32
Study 17106066 — intervention group
Group type: COMPARATOR
Intervention: Control (n=10)
Number of subjects: 32
Study 16297052 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus monotherapy (TACRO)
Number of subjects: 60
Study 16297052 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus plus steroids (TACRO + ST)
Number of subjects: 60
Study 16297052 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus monotherapy (real-TACRO)
Number of subjects: 60
Study 16297052 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus plus steroids (real-TACRO + ST)
Number of subjects: 60
Study 16297052 — intervention group
Group type: EXPERIMENTAL
Intervention: real-TACRO
Number of subjects: 60
Study 16297052 — intervention group
Group type: COMPARATOR
Intervention: real-TACRO + ST
Number of subjects: 60
Study 12139288 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic approach (n = 31)
Number of subjects: 63
Study 12139288 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrogram mapping approach (n = 32)
Number of subjects: 63
Study 9569054 — intervention group
Group type: COMPARATOR
Intervention: FEP regimen (epirubicin 35 mg/m², etoposide 120 mg/m², cisplatin 45 mg/m²)
Number of subjects: 62
Study 9569054 — intervention group
Group type: EXPERIMENTAL
Intervention: FEP regimen plus low-dose GM-CSF (150 microg/day on days 5-14)
Number of subjects: 62
Study 9569054 — intervention group
Group type: COMPARATOR
Intervention: Control group (FEP regimen)
Number of subjects: 62
Study 9569054 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF group (FEP regimen plus GM-CSF)
Number of subjects: 62
Study 8547554 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural hydromorphone
Number of subjects: 20
Study 8547554 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine
Number of subjects: 20
Study 2146272 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 25
Study 2146272 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 25
Study 285045 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy regimen A
Number of subjects: 157
Study 285045 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy regimen B
Number of subjects: 157
Study 285045 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 7601
Number of subjects: 157
Study 285045 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 7602
Number of subjects: 157
Study 285045 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 7603
Number of subjects: 157
Study 31312931 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (CBDCA/PTX)
Number of subjects: 402
Study 31312931 — intervention group
Group type: COMPARATOR
Intervention: Oral uracil-tegafur (UFT)
Number of subjects: 402
Study 28403457 — intervention group
Group type: EXPERIMENTAL
Intervention: MiQuit intervention (tailored text messaging cessation support)
Number of subjects: 15
Study 25753162 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully biodegradable nasal packing Nasopore®
Number of subjects: 83
Study 25753162 — intervention group
Group type: COMPARATOR
Intervention: Control packing (traditional nasal packing)
Number of subjects: 83
Study 24876196 — intervention group
Group type: EXPERIMENTAL
Intervention: DR continuous positive airway pressure
Number of subjects: 0
Study 24876196 — intervention group
Group type: COMPARATOR
Intervention: DR ETI with early surfactant administration
Number of subjects: 0
Study 24876196 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation targets of 85‐89%
Number of subjects: 0
Study 24876196 — intervention group
Group type: COMPARATOR
Intervention: Oxygen saturation targets of 91‐95%
Number of subjects: 0
Study 22476985 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation intervention
Number of subjects: 100
Study 22476985 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 100
Study 19127485 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 0
Study 17403281 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended pancreaticoduodenectomy
Number of subjects: 11
Study 17403281 — intervention group
Group type: COMPARATOR
Intervention: Standard pancreaticoduodenectomy
Number of subjects: 11
Study 15064100 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 281
Study 15064100 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 281
Study 11777965 — intervention group
Group type: EXPERIMENTAL
Intervention: CD40L + IL-1beta
Number of subjects: 0
Study 11777965 — intervention group
Group type: COMPARATOR
Intervention: CD40L
Number of subjects: 0
Study 10353375 — intervention group
Group type: COMPARATOR
Intervention: Healthy adults
Number of subjects: 0
Study 10353375 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic adults
Number of subjects: 0
Study 10353375 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic adults (left visual field)
Number of subjects: 0
Study 10353375 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic adults (right visual field)
Number of subjects: 0
Study 1907566 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (100-200 mg daily)
Number of subjects: 89
Study 1907566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 6136346 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified allergen preparation from Timothy pollen (Timothy N)
Number of subjects: 60
Study 6136346 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude extract from Timothy pollen (Timothy O)
Number of subjects: 60
Study 6136346 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-grass pollen mixture
Number of subjects: 60
Study 6136346 — intervention group
Group type: COMPARATOR
Intervention: Control group (not hyposensitized)
Number of subjects: 60
Study 31973759 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing-based patient empowerment program (PEP), 4 sessions over 1 month
Number of subjects: 225
Study 31973759 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing-based patient empowerment program (PEP)
Number of subjects: 225
Study 31973759 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture-style health education on DM (Control)
Number of subjects: 225
Study 30765503 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Asthma Management System (eAMS)
Number of subjects: 3497
Study 27807040 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention of albendazole (single dose), zinc (14 days), and daily multiple micronutrient powder for 24 weeks
Number of subjects: 254
Study 27807040 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (no interventions)
Number of subjects: 254
Study 26272782 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPOWER intervention (experimental group)
Number of subjects: 0
Study 26272782 — intervention group
Group type: COMPARATOR
Intervention: Healthy Lifestyles (active control intervention)
Number of subjects: 0
Study 24952392 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive stents
Number of subjects: 501
Study 24952392 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents
Number of subjects: 501
Study 22928615 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied on the right side of jaws (GaAlAs LLLT, 670 nm, 5 mW, 14 min/day for five consecutive days)
Number of subjects: 300
Study 22928615 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 300
Study 22928615 — intervention group
Group type: COMPARATOR
Intervention: Control group (periodontitis only)
Number of subjects: 300
Study 21181567 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional multidisciplinary rehabilitation
Number of subjects: 109
Study 21181567 — intervention group
Group type: COMPARATOR
Intervention: Outpatient physiotherapy
Number of subjects: 109
Study 18179322 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs-based model of reconciliation
Number of subjects: 0
Study 16162784 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL of 4% lidocaine (160 mg)
Number of subjects: 150
Study 16162784 — intervention group
Group type: COMPARATOR
Intervention: 4 mL of saline solution as placebo
Number of subjects: 150
Study 16162784 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sedation with 5 mg of IV hydrocodone and midazolam
Number of subjects: 150
Study 14550328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (home-based early intervention with weekly visits for 6 months and biweekly visits from 6 to 18 months)
Number of subjects: 161
Study 14550328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 161